Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Chapman

Showing results (71-80 of 320) with videos related to

Pageof 32
Sort By:
Clinical Cardiology|January 24, 2003
New dimension of statin action on ApoB atherogenicityM John Chapman, Muriel Caslake, Chris Packard, et al.
The Lancet. Diabetes & Endocrinology|December 3, 2014
Treatment of severe hypertriglyceridaemia--authors' replyM John Chapman, Henry N Ginsberg, Robert A Hegele
Current Opinion in Lipidology|January 19, 2016
PCSK9 inhibitors and cardiovascular disease: heralding a new therapeutic eraM John Chapman, Jane K Stock, Henry N Ginsberg, et al.
Pharmacology & Therapeutics|March 19, 2022
Reducing residual cardiovascular risk in Europe: Therapeutic implications of European medicines agency approval of icosapent ethyl/eicosapentaenoic acidM John Chapman, Jose L Zamorano, Klaus G Parhofer
Current Medical Research and Opinion|December 22, 2005
High prevalence of low HDL-cholesterol in a pan-European survey of 8545 dyslipidaemic patientsEric Bruckert, Marie Baccara-Dinet, Fran McCoy, et al.
European Heart Journal Supplements : Journal of the European Society of Cardiology|October 16, 2020
Efficacy and safety of icosapent ethyl in hypertriglyceridaemia: a recapKlaus G Parhofer, M John Chapman, Børge G Nordestgaard
Journal of Clinical Lipidology|March 16, 2022
Concerns regarding NMR lipoprotein analyses performed on the Nightingale heath platform - Focus on LDL subclassesRonald M Krauss, Alan T Remaley, M John Chapman
Atherosclerosis|July 5, 2011
The new joint EAS/ESC guidelines for the management of dyslipidaemiasAlberico L Catapano, John Chapman, Olov Wiklund, et al.
The Journal of Pediatric Pharmacology and Therapeutics : JPPT : the Official Journal of PPAG|May 4, 2023
Comparison of Two Lipid Emulsions on the Incidence of Parenteral Nutrition Associated Cholestasis in NeonatesJoy Greenberg, Mamta Naik, John Chapman, et al.
European Heart Journal|October 15, 2009
Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitorsM John Chapman, Wilfried Le Goff, Maryse Guerin, et al.
Pageof 32

Showing results (71-80 of 320) with videos related to

Sort By:
Pageof 32
Clinical Cardiology|January 24, 2003
New dimension of statin action on ApoB atherogenicityM John Chapman, Muriel Caslake, Chris Packard, et al.
The Lancet. Diabetes & Endocrinology|December 3, 2014
Treatment of severe hypertriglyceridaemia--authors' replyM John Chapman, Henry N Ginsberg, Robert A Hegele
Current Opinion in Lipidology|January 19, 2016
PCSK9 inhibitors and cardiovascular disease: heralding a new therapeutic eraM John Chapman, Jane K Stock, Henry N Ginsberg, et al.
Pharmacology & Therapeutics|March 19, 2022
Reducing residual cardiovascular risk in Europe: Therapeutic implications of European medicines agency approval of icosapent ethyl/eicosapentaenoic acidM John Chapman, Jose L Zamorano, Klaus G Parhofer
Current Medical Research and Opinion|December 22, 2005
High prevalence of low HDL-cholesterol in a pan-European survey of 8545 dyslipidaemic patientsEric Bruckert, Marie Baccara-Dinet, Fran McCoy, et al.
European Heart Journal Supplements : Journal of the European Society of Cardiology|October 16, 2020
Efficacy and safety of icosapent ethyl in hypertriglyceridaemia: a recapKlaus G Parhofer, M John Chapman, Børge G Nordestgaard
Journal of Clinical Lipidology|March 16, 2022
Concerns regarding NMR lipoprotein analyses performed on the Nightingale heath platform - Focus on LDL subclassesRonald M Krauss, Alan T Remaley, M John Chapman
Atherosclerosis|July 5, 2011
The new joint EAS/ESC guidelines for the management of dyslipidaemiasAlberico L Catapano, John Chapman, Olov Wiklund, et al.
The Journal of Pediatric Pharmacology and Therapeutics : JPPT : the Official Journal of PPAG|May 4, 2023
Comparison of Two Lipid Emulsions on the Incidence of Parenteral Nutrition Associated Cholestasis in NeonatesJoy Greenberg, Mamta Naik, John Chapman, et al.
European Heart Journal|October 15, 2009
Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitorsM John Chapman, Wilfried Le Goff, Maryse Guerin, et al.
Pageof 32